Clinical Trial

Effect of L-ornithine-L-aspertate (LOLA) on the Gut Microbiome

Study acronym: LOLAbiome
Active, Not Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
Study to test the effect of the drug "L-ornithine.L-aspertate" (LOLA) on microorganisms in the digestive tract in patients with liver cirrhosis (damage of the liver due to liver disease)
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2023-02-12; most recent amendment 2025-02-06.
Status change: Recruiting → Active, Not Recruiting 2025-02-06
Trial Details
NCT Number NCT05737030
Lead Sponsor Medical University of Graz
Collaborators: CBmed Ges.m.b.H.
Conditions Cirrhosis
Enrollment 55 participants
Start Date 2023-02-06
Primary Completion 2024-07-23 (estimated)
Study Completion 2025-12 (estimated)
Updated on ClinicalTrials.gov 2025-02-10